Biotechnology ResearchAlberta, Canada11-50 Employees
Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments.
| Oncolytics Biotech Inc. Email Formats | Percentage |
| FLast@oncolytics.ca | 72% |
| FirstL@oncolytics.ca | 19% |
| Last@oncolytics.ca | 3% |
| FirstLast@oncolytics.ca | 4% |
| First.Last@oncolytics.ca | 2% |
| First.Last@oncolyticsbiotech.com | 50% |
| First.Last@oncolyticsbiotech.com | 50% |
Check if your email matches the formats in our database with our efficient email format checker tool.
| Matching Format | Percentage |
| FLast@oncolytics.ca | 72% |
| FirstL@oncolytics.ca | 19% |
| Last@oncolytics.ca | 3% |
| FirstLast@oncolytics.ca | 4% |
| First.Last@oncolytics.ca | 2% |
| First.Last@oncolyticsbiotech.com | 50% |
| First.Last@oncolyticsbiotech.com | 50% |
Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.
1-888-653-2347 
support@leadiq.com